PFE: Sigvie-002 Trial Fails
Pfizer's Phase 3 Sigvie-002 trial of Sigvotatug Vedotin in advanced NSCLC did not meet primary endpoint of OS versus Docetaxel
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.